Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Gender Influences the Clinical Presentation and Long-Term Outcome of Graves’ Disease
source: Endocrine Practice
year: 2016
authors: Magri F, Zerbini F, Gaiti M, Capelli V, Ragni A, Rotondi M, Chiovato L
summary/abstract:Objective:
The outcome of antithyroid drug (ATD) treatment for Graves disease (GD) is difficult to predict. In this study, we investigated whether male gender, besides other factors usually associated with a poor outcome of ATD treatment, may affect disease presentation and predict the response to medical treatment in subjects with GD.
Methods:
We studied 294 patients with a first diagnosis of GD. In all patients, ATD treatment was started. Clinical features, thyroid volume, and eye involvement were recorded at baseline. Serum levels of free thyroxine (FT4), free triiodothyronine (FT3), thyroid-stimulating hormone (TSH), and TSH-receptor antibodies (TRAb) were measured at baseline and during the follow-up. Treatment outcome (FT4, FT3, and TSH serum levels and further treatments for GD after ATD withdrawal) was evaluated.
Results:
When compared to women, men showed a significantly larger thyroid volume and a higher family positivity for autoimmune diseases. During ATD, the mean serum levels of TSH, FT4, FT3, and TRAb did not differ between groups. Within 1 year after ATD discontinuation, relapse of hyperthyroidism was significantly more frequent in men than in women. Within the 5-year follow-up period, the prevalence of men suffering a late relapse was higher compared with that of women. The outcome at the end of the 5-year follow-up period was significantly associated with gender and TRAb levels at disease onset.
Conclusion:
Male patients with GD have a poorer prognosis when submitted to medical treatment with ATDs. A larger goiter at presentation and a stronger genetic autoimmune background might explain this gender difference in patients with GD.
DOI: 10.4158/EP161350.OR
read more
Related Content
-
Predicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
-
Effect of Long-Term Continuous Methimazole Treatment of Hyperthyroidism: Comparison With RadioiodineObjective: To investigate the long-term...
-
A 6-Year Follow-Up of a Randomized Prospective Trial Comparing Methimazole Treatment With or Without Exogenous L-Thy...Objective: Antithyroid drug therapy is ...
-
Graves’ Disease Treatment for Someone in Their 20sHyperthyroidism triggered by Graves’ d...
-
Advances in Treatment of Active, Moderate-To-Severe Graves’ OphthalmopathyGraves' ophthalmopathy is defined as aut...
-
Effects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: ...Objective: In spite of previous conflic...
-
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ D...Over-activity of the thyroid gland, call...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.